Navigation Links
Southern Research Institute Names Vladimir Yamshchikov Director of Infectious Disease Research Department in Birmingham
Date:11/5/2007

BIRMINGHAM, Ala., Nov. 5 /PRNewswire-USNewswire/ -- Southern Research Institute, a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery, drug and vaccine development, advanced engineering, environmental and energy production, today announced the appointment of Vladimir Yamshchikov, Ph.D. as director of its Infectious Disease Research Dept. in Birmingham.

(Photo: http://www.newscom.com/cgi-bin/prnh/20071105/6371)

"Dr. Yamshchikov has an impressive combination of scientific, technical and regulatory expertise, with more than 20 years experience with research in molecular virology in BSL-3 and ABSL-3 laboratories," said William R. Waud, Ph.D., interim vice president of the Drug Development Division at Southern Research. "His intimate knowledge and experience working with infectious diseases and select agents will serve him well as he manages this growing area of research at Southern Research."

Prior to joining Southern Research, Dr. Yamshchikov was an associate professor in the Department of Molecular Biosciences at the University of Kansas. He is a member of the American Society for Virology and has published more than 35 peer-reviewed research papers. He received his Master's degree in Bioorganic Chemistry from Moscow State University in Moscow, Russia and his doctorate in Bioorganic Chemistry & Molecular Biology from the Institute of Bioorganic Chemistry in Novosibirsk, Russia.

Dr. Yamshchikov has extensive experience and training in handling emerging pathogens and select agents in both BSL-3 and ABSL-3 laboratories. He also has hands-on experience working with a variety of human and veterinary pathogens and viral vectors. He spent more than 10 years managing a CDC/USDA certified BSL-3 and ABSL-3 facility approved by the FBI to handle select agents.

Southern Research also operates an Infectious Disease Research Dept. in Frederick, Md., directed by Michael G. Murray, Ph.D. Last year, Southern Research's BSL-3 laboratory in Birmingham underwent a $1 million renovation that included adding bioaerosol capabilities and expanding Southern Research's ability to conduct GLP-compliant studies in high containment, and to evaluate and test new therapeutics and vaccines to protect the public against select agents and emerging infectious diseases. The BSL-3 contains more than 8,300 square feet of in vitro and in vivo space. It is registered with the Centers for Disease Control (CDC) and the U.S. Department of Agriculture (USDA) to work with both animal and human risk group Level 3 pathogens, including highly-pathogenic avian influenza (HPAi), West Nile, SARS viruses and Bacillus anthracis (anthrax).

About Southern Research Institute

Southern Research Institute is a not-for-profit organization that conducts basic and applied research in the areas of preclinical drug discovery, vaccine and drug development, advanced engineering, environmental research and energy production. To date, Southern Research has discovered six FDA-approved cancer drugs and discovered six additional drugs that are currently in late stage preclinical and early clinical trials. No other company or institution has brought six of its own cancer drug discoveries to market. For more information, please visit http://www.southernresearch.org.


'/>"/>
SOURCE Southern Research Institute
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
2. USAID Assistant Administrator Hess Travels to Southern Africa
3. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
4. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
5. Angel Flight West Recognizes Southern California Pilots at 24th Anniversary
6. Southern California Wildfires Continue to Threaten Residential Areas
7. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
8. VA Remains Open for Care for Southern California Vets
9. Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts
10. The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires
11. CNA/NNOC Nurse Volunteers Deployed to Southern California Firestorm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... ... April 29, 2017 , ... ... and recognize the positive impact veterinarians have on animal health and welfare as ... Organization for Animal Health (OIE) choose a theme each year and this year ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... National Campaign) announces its support for the Access to Contraception for Women Servicemembers ... (D-NH) and Rep. Jackie Speier (D-CA), will help to ensure that all members ...
(Date:4/28/2017)... ... April 28, 2017 , ... It's not always common knowledge whether or not ... are unclear as to whether or not they are contagious, and most people don't ... illnesses. So, FindaTopDoc took a look into the matter. , They discovered that ...
(Date:4/28/2017)... ... , ... Beginning in 2017, Ridgecrest Herbals will be phasing out the homeopathic ... Extra Strength formula. To ensure that the effectiveness of Clear Lungs Extra Strength is ... , Removal of the homeopathic element , Adding their patented ...
(Date:4/28/2017)... ... , ... Getting enough sleep affects much more than energy – it also has mental and ... can compromise motor reaction time, which can increase the risk of having a car accident. ... tips from the NSF to help you sleep better and feel better:, ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: